References
- Hetrick DC, Ciol MA, Rothman I, Turner JA, Frest M, Berger RE. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III: a case–control study. J Urol 2003;170:828–31.
- Berger RE, Ciol MA, Rothman I, Turner JA. Pelvic tenderness is not limited to the prostate in chronic prostatitis/chronic pelvic pain syndrome (CPPS) type IIIA and IIIB: comparison of men with and without CP/CPPS. BMC Urol 2007;7:7.
- FitzGerald MP, Anderson RU, Potts J, Payne CK, Peters KM, Clemens JQ, Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 2009;182:570–80.
- Anderson RU, Wise D, Sawyer T, Chan C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol 2005;174:155–60.
- Coelho A, Dinis P, Pinto R, Gorgal T, Silva C, Silva A, Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2009; Dec 29 [Epub].
- Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009;28:72:1473–8.
- Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712–7.
- Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005;118:170–5.
- Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274–83.
- Hetrick DC, Glazer H, Liu YW, Turner JA, Frest M, Berger RE. Pelvic floor electromyography in men with chronic pelvic pain syndrome: a case–control study. Neurourol Urodyn 2006;25:46–9.
- Zermann D, Ishigooka M, Schubert J, Schmidt RA. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 2000;38:393–9.
- Bschleipfer T, Wagenlehner FM, Weidner W. Intraprostatic botulinum toxin A injection in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Urologe A 2007;46:1030–2.
- Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;162:369–75.
- Propert KJ, Litwin MS, Wang Y, Alexander RB, Calhoun E, Nickel JC, Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Qual Life Res 2006;15:299–305.
- Chuang YC, Yoshimura N, Huang CC, Wu M, Chiang PH, Chancellor MB. Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J Urol 2008;180:742–8.
- Baranowski AP, Abrams P, Berger RE, Buffington CA, de C Williams AC, Hanno P, Urogenital pain – time to accept a new approach to phenotyping and, as a consequence, management. Eur Urol 2008;53:33–6.
- Tripp DA, Nickel JC, Fitzgerald MP, Mayer R, Stechyson N, Hsieh A. Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. Urology 2009;73:987–92.
- Pezzone MA, Liang R, Fraser MO. A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterology 2005;128:1953–64.